SHR-A1811 & Bevacizumab injection

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Peking Union Medical College Hospital

Conditions

Antibody-drug ConjugatesHER2HER2 Low Advanced or Metastatic Breast CancerTargeted TherapymCRC

Phase 1

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

Jiangsu HengRui Medicine Co., Ltd.HER2 Low Advanced or Metastatic Breast Cancer

Start: 2023-04-30End: 2025-02-27Target: 300Updated: 2023-03-31

Phase 2

MA-CRC-II-016 SHR-1811

Not yet recruitingNCT07355764

Peking Union Medical College HospitalAntibody-drug Conjugates, HER2, mCRC +1

Start: 2025-12-30End: 2028-01-31Target: 80Updated: 2026-01-21